Evidence map›Paper›PMID 41129722›Full record

ReviewHuman vaccines & immunotherapeutics2025

Invasive meningococcal disease in adolescents in Europe and select geographies: Disease burden, unmet medical need, and optimizing prevention.

Anar Andani, Victoria Abbing-Karahagopian, Justina Kavaliauskaite, Thierry Oliver Schaffner, Woo-Yun Sohn, Maria Gabriela Graña, Helen Marshall, Federico Martinon-Torres, Paolo Bonanni, Rino Rappuoli and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anar AndaniGSK, Medical Affairs, Wavre, Belgium.ORCID 0000-0003-0530-5340
Victoria Abbing-KarahagopianGSK Vaccines, Epidemiology, Amsterdam, The Netherlands.
Justina KavaliauskaiteGSK, Medical Affairs, Wavre, Belgium.
Thierry Oliver SchaffnerGSK, Medical Affairs, Baar, Switzerland.
Woo-Yun SohnGSK, Medical Affairs, Rockville, MD, USA.
Maria Gabriela GrañaGSK Vaccines, Medical Affairs, Santiago, Chile.
Helen MarshallDiscipline of Paediatrics and Robinson Research Institute, The University of Adelaide and Women's and Children's Health Network, Adelaide, Australia.
Federico Martinon-TorresTranslational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.
Paolo BonanniDepartment of Health Sciences, University of Florence, Florence, Italy.
Rino RappuoliFondazione Biotecnopolo di Siena, Siena, Italy.
Muhamed-Kheir TahaInvasive Bacterial Infections Unit, National Reference Centre for Meningococci and Haemophilus Influenzae, WHO Collaborating Center for Meningitis, Institut Pasteur, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive meningococcal disease (IMD) is uncommon but serious; the case fatality rate is 8-15% and up to 20-40% of survivors experience disabling sequelae, with a substantial socioeconomic impact. Although incidence is highest in infants and young children (aged ≤4 y), a second epidemiologic peak occurs in adolescents and young adults (aged 15-24 y), who are the main carriers of

Indexed as

Meningococcal InfectionsMeningococcal VaccinesAdolescentAustraliaBrazilCost of IllnessEuropeHumansImmunization ProgramsIncidenceNeisseria meningitidisNew ZealandVaccinationVaccination CoverageYoung AdultMeningococcal Vaccinesadolescentsdisease burdenepidemiologyEuropeguidelinesimmunization programsInvasive meningococcal diseaseNeisseria meningitidispreventionvaccines

Identifiers

PMID41129722
PMCPMC12562678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.